Country: Canada
Language: English
Source: Health Canada
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; LACTIC ACID; SODIUM CHLORIDE; SODIUM BICARBONATE
BAXTER CORPORATION
B05ZA
HEMODIALYTICS, CONCENTRATES
5.145G; 2.033G; 5.4G; 6.45G; 3.09G
SOLUTION
CALCIUM CHLORIDE 5.145G; MAGNESIUM CHLORIDE 2.033G; LACTIC ACID 5.4G; SODIUM CHLORIDE 6.45G; SODIUM BICARBONATE 3.09G
INTRAVENOUS
4750/5000 ML
Ethical
HEMODIALYSIS SOLUTION
Active ingredient group (AIG) number: 0552651001; AHFS:
APPROVED
2010-07-23
_ _ _PrismaSOL 0 _ _Page 1 of 20_ PRESCRIBING INFORMATION PRISMASOL 0 Calcium chloride dihydrate 5.145 g/L, Lactic acid 5.4 g/L, Magnesium chloride hexahydrate 2.033 g/L, Sodium bicarbonate 3.09 g/L, and Sodium chloride 6.45 g/L solution Sterile solution for hemofiltration and hemodialysis Hemodialytics, concentrates, ATC code: B05Z A BAXTER CORPORATION. MISSISSAUGA, ON CANADA, L5N 0C2 Date of Initial Approval: January 1, 2001 Date of Revision: February 27, 2019 Submission Control No: 218869 Baxter and PrismaSOL are trademarks of Baxter International Inc., or its subsidiaries. _ _ _PrismaSOL 0 _ _Page 2 of 20_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................6 DRUG INTERACTIONS ....................................................................................................7 DOSAGE AND ADMINISTRATION ................................................................................8 OVERDOSAGE ..................................................................................................................9 ACTION AND CLINICAL PHARMACOLOGY ..............................................................9 STORAGE AND STABILITY ..........................................................................................10 SPECIAL HANDLING INSTRUCTIONS .......................................................................11 DOSAGE FORMS, COMPOSITION AND PACKAGING .......................................... Read the complete document